High blood pressure news and high blood pressure widget

Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced positive results from a Phase 1a clinical trial of MBX-2982. A summary of the results was presented at the World Congress on Controversies to Consensus in diabetes, Obesity and Hypertension (CODHy) on November 1, 2008.

NicOx S.A. (Euronext Paris: COX) announced that a new analysis of the data from the 104 Ambulatory Blood Pressure Monitoring (ABPM) study for naproxcinod was presented yesterday at the American Heart Association Scientific Sessions 2008, in New Orleans, USA. This ABPM pilot study in hypertensive volunteers was designed to compare the 24-hour blood pressure profiles of naproxcinod 750 mg bid and naproxen 500 mg bid.

More than half of people diagnosed with high blood pressure do not have it under control and many more go undiagnosed, according to research carried out at the University of Warwick. Professor Franco Cappuccio from Warwick Medical School at the University of Warwick led the only UK team to participate in a European study examining awareness, treatment and control of high blood pressure, or hypertension.

Title: Education Program Spurs Blacks to Take Blood Pressure MedsCategory: health newscreated: 11/13/2008 2:00:00 amlast Editorial review: 11/13/2008